(BIM) Biomerieux - Overview
Sector: Healthcare | Industry: Diagnostics & Research | Exchange: PA (France) | Market Cap: 8.699m EUR | Total Return: -38.6% in 12m
Avg Turnover: 14.4M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
bioMérieux S.A. (BIM) is a French-based diagnostics firm specializing in in vitro solutions for infectious disease management. The company operates through two primary segments: Clinical Applications, which focuses on medical diagnostics like sepsis and respiratory infections, and Industrial Applications, which provides microbiological testing for the food and pharmaceutical sectors. Its product portfolio includes automated blood culture systems, multiplex PCR platforms, and antimicrobial susceptibility testing (AST) technologies.
The in vitro diagnostics (IVD) sector is characterized by high barriers to entry due to stringent regulatory requirements and the need for significant R&D investment to maintain technological relevance. bioMérieux utilizes a razor-and-blade business model, where the placement of proprietary diagnostic instruments generates a recurring revenue stream through the subsequent sale of specialized reagents and consumables. This strategy provides long-term visibility into cash flows as clinical labs become integrated into the companys software and hardware ecosystem.
For a deeper look into the companys fundamental performance, consider reviewing the detailed valuation metrics available on ValueRay. bioMérieux remains a key player in the global effort to combat antimicrobial resistance, leveraging its mass spectrometry and genomic sequencing tools to provide rapid identification of pathogens.
- BIOFIRE multiplex PCR system adoption drives core clinical revenue growth
- Expansion into point-of-care diagnostics through SPOTFIRE increases market share
- Industrial microbiology demand for food and pharmaceutical safety stabilizes margins
- Antimicrobial susceptibility testing leadership benefits from global antibiotic resistance trends
- Fluctuating respiratory virus seasons create volatility in molecular diagnostic sales volume
| Net Income: 681.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.14 > 0.02 and ΔFCF/TA 10.11 > 1.0 |
| NWC/Revenue: 21.29% < 20% (prev 21.73%; Δ -0.44% < -1%) |
| CFO/TA 0.26 > 3% & CFO 1.46b > Net Income 681.4m |
| Net Debt (300.1m) to EBITDA (1.60b): 0.19 < 3 |
| Current Ratio: 2.39 > 1.5 & < 3 |
| Outstanding Shares: last quarter (119.0m) vs 12m ago 0.33% < -2% |
| Gross Margin: 53.06% > 18% (prev 0.53%; Δ 5.25k% > 0.5%) |
| Asset Turnover: 127.3% > 50% (prev 104.8%; Δ 22.44% > 0%) |
| Interest Coverage Ratio: 41.54 > 6 (EBITDA TTM 1.60b / Interest Expense TTM 22.6m) |
| A: 0.26 (Total Current Assets 2.54b - Total Current Liabilities 1.06b) / Total Assets 5.57b |
| B: 0.07 (Retained Earnings 397.5m / Total Assets 5.57b) |
| C: 0.17 (EBIT TTM 940.9m / Avg Total Assets 5.45b) |
| D: 0.28 (Book Value of Equity 409.5m / Total Liabilities 1.47b) |
| Altman-Z'' = 3.42 = A |
| DSRI: 0.92 (Receivables 1.01b/888.6m, Revenue 6.93b/5.58b) |
| GMI: 0.99 (GM 53.06% / 52.57%) |
| AQI: 0.86 (AQ_t 0.25 / AQ_t-1 0.29) |
| SGI: 1.24 (Revenue 6.93b / 5.58b) |
| TATA: -0.14 (NI 681.4m - CFO 1.46b) / TA 5.57b) |
| Beneish M = -3.16 (Cap -4..+1) = AA |
As of May 27, 2026, the stock is trading at EUR 71.90 with a total of 114,592 shares traded.
Over the past week, the price has changed by -0.42%,
over one month by +0.84%,
over three months by -25.41% and
over the past year by -38.56%.
Biomerieux has no consensus analysts rating.
P/E Trailing = 22.0808
P/E Forward = 17.6056
P/S = 2.1375
P/B = 2.089
P/EG = 1.3357
Revenue TTM = 6.93b EUR
EBIT TTM = 940.9m EUR
EBITDA TTM = 1.60b EUR
Long Term Debt = 211.3m EUR (from longTermDebt, last quarter)
Short Term Debt = 131.4m EUR (from shortTermDebt, last quarter)
Debt = 612.2m EUR (from shortLongTermDebtTotal, last quarter) + Leases 150.8m
Net Debt = 300.1m EUR (calculated: Debt 612.2m - CCE 312.1m)
Enterprise Value = 9.00b EUR (8.70b + Debt 612.2m - CCE 312.1m)
Interest Coverage Ratio = 41.54 (Ebit TTM 940.9m / Interest Expense TTM 22.6m)
EV/FCF = 11.62x (Enterprise Value 9.00b / FCF TTM 774.5m)
FCF Yield = 8.61% (FCF TTM 774.5m / Enterprise Value 9.00b)
FCF Margin = 11.17% (FCF TTM 774.5m / Revenue TTM 6.93b)
Net Margin = 9.83% (Net Income TTM 681.4m / Revenue TTM 6.93b)
Gross Margin = 53.06% ((Revenue TTM 6.93b - Cost of Revenue TTM 3.25b) / Revenue TTM)
Gross Margin QoQ = 49.00% (prev 57.09%)
Tobins Q-Ratio = 1.61 (Enterprise Value 9.00b / Total Assets 5.57b)
Interest Expense / Debt = 3.70% (Interest Expense 22.6m / Debt 612.2m)
Taxrate = 24.39% (76.2m / 312.4m)
NOPAT = 711.4m (EBIT 940.9m * (1 - 24.39%))
Current Ratio = 2.39 (Total Current Assets 2.54b / Total Current Liabilities 1.06b)
Debt / Equity = 0.15 (Debt 612.2m / totalStockholderEquity, last quarter 4.10b)
Debt / EBITDA = 0.19 (Net Debt 300.1m / EBITDA 1.60b)
Debt / FCF = 0.39 (Net Debt 300.1m / FCF TTM 774.5m)
Total Stockholder Equity = 4.03b (last 4 quarters mean from totalStockholderEquity)
RoA = 12.51% (Net Income 681.4m / Total Assets 5.57b)
RoE = 16.92% (Net Income TTM 681.4m / Total Stockholder Equity 4.03b)
RoCE = 22.20% (EBIT 940.9m / Capital Employed (Equity 4.03b + L.T.Debt 211.3m))
RoIC = 15.33% (NOPAT 711.4m / Invested Capital 4.64b)
WACC = 6.26% (E(8.70b)/V(9.31b) * Re(6.50%) + D(612.2m)/V(9.31b) * Rd(3.70%) * (1-Tc(0.24)))
Discount Rate = 6.50% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 22.47 | Cagr: 0.03%
[DCF] Terminal Value 77.97% ; FCFF base≈545.2m ; Y1≈625.0m ; Y5≈919.8m
[DCF] Fair Price = 114.8 (EV 13.8b - Net Debt 300.1m = Equity 13.5b / Shares 118.0m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: -23.13 | Revenue CAGR: -3.97% | SUE: -0.03 | # QB: 0
EPS current Year (2026-12-31): EPS=4.49 | Chg30d=-5.35% | Revisions=-29% | GrowthEPS=-3.3% | GrowthRev=+2.1%
EPS next Year (2027-12-31): EPS=4.98 | Chg30d=-6.97% | Revisions=-43% | GrowthEPS=+11.1% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: -43%